过去一年中添加的文章，按日期排序
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy
MY Jeng, HA Yu - Journal of Clinical Oncology, 2024 - ascopubs.org
31 天前 - … among patients with non–small cell lung cancer (NSCLC), … treatment modalities
such as systemic chemotherapy, brain… EGFR mutations non–small cell lung cancer patients with …
such as systemic chemotherapy, brain… EGFR mutations non–small cell lung cancer patients with …
Systemic treatment of EGFR-mutated non-small cell lung cancer
R Czyżykowski, EK Wrona, A Tałajko… - Oncology in Clinical …, 2024 - journals.viamedica.pl
32 天前 - … -cell lung cancer; therefore screening for EGFR mutations is mostly restricted to …
EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and …
EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and …
[HTML][HTML] Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study
RA Soo, T Reungwetwattana, HA Perroud… - Journal of Thoracic …, 2024 - Elsevier
45 天前 - … Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely
resected non-small-cell lung cancer: ASCO guideline rapid recommendation update …
resected non-small-cell lung cancer: ASCO guideline rapid recommendation update …
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced …
R Bartsch, M Vaz Batista, AS Berghoff, J Furtner… - 2024 - ascopubs.org
61 天前 - … incidence of BM is observed in advanced non–small cell lung cancer (aNSCLC)
and metastatic breast cancer … , ≥1 line of prior systemic treatment, histologically documented …
and metastatic breast cancer … , ≥1 line of prior systemic treatment, histologically documented …
… of carcinoembryonic antigen-related cell adhesion molecule 5 expression by immunohistochemistry in real-world clinical samples of non-small cell lung cancer.
YHR Hsu, A Almutrafi, K Hueniken, MS Tsao - 2024 - ascopubs.org
61 天前 - … has not been systematically examined in a real-world patient population with NSCLC.
… in neoplastic cells, but was consistently absent in nonneoplastic cells. The prevalence of …
… in neoplastic cells, but was consistently absent in nonneoplastic cells. The prevalence of …
Comprehensive characterization of ERBB2 genomic alterations inlung cancer.
T El Zarif, P Stockhammer, J Schillo, SB Goldberg… - 2024 - ascopubs.org
61 天前 - … () occur in 1-4% of non-small cell lung cancers (NSCLC). … (PFS) with first-line systemic
therapy, and log-rank tests … without ERBB2amplifications had a higher frequency of TP53 …
therapy, and log-rank tests … without ERBB2amplifications had a higher frequency of TP53 …
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
61 天前 - … Methods: Using a retrospective cohort of NSCLC patients from Penn State Health
(2011… systematically identified, and 2) developed nomograms to predict risk of BM incidence. …
(2011… systematically identified, and 2) developed nomograms to predict risk of BM incidence. …
Next-generation sequencing (NGS) completion and timeliness using reflex testing protocol for patients with stage II-III non-squamous non-small cell lung cancer (NS …
S Maheshwari, G Smilnak, R Singh, E Williams… - 2024 - ascopubs.org
61 天前 - … , or systemic therapy. Actionable mutation incidence, proportion of patients with
test … The majority of patients had NGS results available to inform systemic therapy decisions …
test … The majority of patients had NGS results available to inform systemic therapy decisions …
Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors.
FJ Lin, WY Lin, CC Wang, JY Shih - 2024 - ascopubs.org
61 天前 - … modality for EGFR-mutant non-small cell lung cancer (NSCLC). … TKIs within two
distinct healthcare delivery systems in … Gefitinib showed the lowest incidence rates across all …
distinct healthcare delivery systems in … Gefitinib showed the lowest incidence rates across all …
Treating lung cancer in resource limited setting: Retrospective study from Armenia.
M Mailyan, D Zohrabyan, L Safaryan, L Harutyunyan… - 2024 - ascopubs.org
61 天前 - … by incidence in Armenia. Every year approximately 800-900 … 74% of patients had
non small cell lung cancer (NSCLC), … For stage I-III LC patients, those who received systematic …
non small cell lung cancer (NSCLC), … For stage I-III LC patients, those who received systematic …